<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974909</url>
  </required_header>
  <id_info>
    <org_study_id>09-2-079</org_study_id>
    <secondary_id>NL 28955.068.09</secondary_id>
    <secondary_id>MEC 09-2-079</secondary_id>
    <nct_id>NCT00974909</nct_id>
  </id_info>
  <brief_title>Percutaneous Tibial Nerve Stimulation in the Treatment of Fecal Incontinence</brief_title>
  <official_title>Percutaneous Tibial Nerve Stimulation in the Treatment of Fecal Incontinence: a Multi-center, Randomized, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background of the study:&#xD;
&#xD;
      Fecal incontinence is a complex problem. The social consequences of this problem result in a&#xD;
      lower quality of life. The exact prevalence of FI is unknown, literature reports vary from&#xD;
      13-19%. There are variable treatment options depending on the patient and the etiology of the&#xD;
      FI. Dietary manipulation, pharmacological intervention, pelvic floor physiotherapy, as well&#xD;
      as surgical interventions are currently used to treat FI.&#xD;
&#xD;
      A promising current treatment is Percutaneous Tibial Nerve Stimulation (PTNS). The nerves in&#xD;
      the spine that control bowel function also have branches which go to the ankle. Stimulating&#xD;
      these nerves in the ankle has shown to be an effective treatment for FI in the short-term.&#xD;
      The treatment has been shown to be safe and well tolerated by subjects with almost no&#xD;
      morbidity in prior urology trials.&#xD;
&#xD;
      Objective of the study:&#xD;
&#xD;
      The objective of this study is to show that the results of PTNS are based on the treatment of&#xD;
      electrical stimulation and not on a placebo effect with a sham treatment.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      This study is a multicenter, single-blinded, randomized, placebo-controlled trial.&#xD;
&#xD;
      Primary study parameters/outcome of the study:&#xD;
&#xD;
      The percentage of patients experiencing a ≥ 50% decrease in incontinence episodes from&#xD;
      baseline after 9 weeks of treatment.&#xD;
&#xD;
      Secondary study parameters/outcome of the study (if applicable):&#xD;
&#xD;
      Mean change in the Cleveland Clinic Florida Fecal Incontinence Score (CCF-FI Score)&#xD;
&#xD;
      Mean change in Quality of Life scores in validated QoL questionnaires (SF-36, Digestive&#xD;
      Health Status Instrument (DHSI), and Fecal Incontinence Quality of life)&#xD;
&#xD;
      Subject's and Physician's Global Impression&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients experiencing a ≥ 50% decrease in incontinence episodes from baseline after 9 weeks of treatment and at six and twelve months follow-up.</measure>
    <time_frame>9 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in the Cleveland Clinic Florida Fecal Incontinence Score (CCF-FI Score) at 6 weeks and 9 weeks of treatment and at six and twelve months follow-up.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Quality of Life scores in validated QoL questionnaires (SF-36, Digestive Health Status Instrument (DHSI), and Fecal Incontinence Quality of life) at 6 weeks and 9 weeks of treatment and at six and twelve months follow-up.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's and Physician's Global Impression at 6 weeks and 9 weeks of treatment and at six and twelve months follow-up.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Urgent PC neuromodulation system</intervention_name>
    <description>Urgent PC neuromodulation system</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Urgent PC neuromodulation system</intervention_name>
    <description>Urgent PC neuromodulation system (sham)</description>
    <arm_group_label>sham group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Must be at least 18 years of age&#xD;
&#xD;
          -  Fecal incontinence with solid or liquid stool causing disruption of the subject's&#xD;
             lifestyle&#xD;
&#xD;
          -  Psychological stability as determined by treating physician&#xD;
&#xD;
          -  Willingness to commit to a rigid follow-up schedule and comply with the&#xD;
             investigational plan&#xD;
&#xD;
          -  Failed conservative therapy (i.e. dietary and behavioural modification, biofeedback&#xD;
             techniques and exercises for pelvic floor muscle retraining)&#xD;
&#xD;
          -  During treatment the patient exhibits an adequate motor and/or sensory response&#xD;
             (flexion of toe and/or twinkling sensation)&#xD;
&#xD;
          -  Is able to read and write&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major internal and/or external sphincter defect (defined as &gt;33% of the anal&#xD;
             circumference)&#xD;
&#xD;
          -  Fecal impaction&#xD;
&#xD;
          -  Pacemaker, implanted defibrillator&#xD;
&#xD;
          -  Pregnancy or intention to become pregnant&#xD;
&#xD;
          -  Neurogenic or congenital disorders resulting in FI&#xD;
&#xD;
          -  Inability to travel to the clinic twice a week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelius Baeten, prof phd md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCDE - IMAD - Hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>F - 44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Roma &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht university medical center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>August 25, 2015</last_update_submitted>
  <last_update_submitted_qc>August 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fecal incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

